Lexaria Bioscience Corp. (LEXX)

Market Cap	14.68M -32.0%
Revenue (ttm)	368,000 -30.0%
Net Income	-9.53M
EPS	-0.46
Shares Out	24.79M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	43,792
Open	0.6220
Previous Close	0.6109
Day's Range	0.5805 - 0.6229
52-Week Range	0.4600 - 1.5500
Beta	0.36
Analysts	Strong Buy
Price Target	1.50 (+153.29%)
Earnings Date	Apr 13, 2026

About LEXX

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: LEXX
• Website: https://lexariabioscience.com

Financial Performance

In fiscal year 2025, Lexaria Bioscience's revenue was $705,923, an increase of 52.05% compared to the previous year's $464,278. Losses were -$11.90 million, 105.4% more than in 2024.

Analyst Summary

According to one analyst, the rating for LEXX stock is "Strong Buy" and the 12-month stock price target is $1.5.

Price Target

$1.5

(153.29% upside)

Analyst Consensus: Strong Buy